Literature DB >> 30265757

Assessment of HIV transfusion transmission risk in South Africa: a 10-year analysis following implementation of individual donation nucleic acid amplification technology testing and donor demographics eligibility changes.

Marion Vermeulen1, Nico Lelie2, Charl Coleman1, Wendy Sykes1, Genevieve Jacobs1, Ronel Swanevelder1, Michael Busch3, Gert van Zyl4,5, Eduard Grebe6, Alex Welte6, Ravi Reddy1.   

Abstract

BACKGROUND: In 1998 we estimated that 34/million infectious window period donations were entering the blood supply at the South African National Blood Service. Selective use of donations based on donor race-ethnicity reduced this risk to 26/million donations but was deemed unethical. Consequently, in 2005 South African National Blood Service eliminated race-ethnicity-based collection policies and implemented individual-donation nucleic acid testing (ID-NAT). We describe the change in donor base demographics, human immunodeficiency virus (HIV) detection rates, and transfusion-transmissible HIV risk. STUDY DESIGN AND METHODS: In ten years 7.7 million donations were tested for anti-HIV and HIV RNA. Number of donations, HIV prevalence, ID-NAT yield rate, serology yield rate and residual transfusion-transmissible HIV risk were analyzed by donor type, race-ethnicity, age, and sex. Multiple regression analysis was performed to investigate the determinants of HIV-positive and nucleic acid testing yield donations.
RESULTS: The combined strategy of increasing donations from black donors and implementing ID-NAT increased the proportion of donations from black donors from 6% in 2005 to 30% in 2015 (p < 0.00001), and reduced the transfusion-transmissible risk from 24 to 13 per million transfusions. ID-NAT interdicted 481 (1:16,100) seronegative window period donations, while one transfusion-transmissible case (0.13 per million) was documented. Race-ethnicity and donor type were highly significant predictors of HIV positivity, with adjusted odds ratio for first-time donors of 12.5 (95% confidence interval, 11.9-13.1) and for black race-ethnicity of 31.1 (95% confidence interval, 28.9-33.4). The proportion of serology yields among HIV-infected donors increased from 0.27% to 2.4%.
CONCLUSION: ID-NAT enabled the South African National Blood Service to increase the number of donations from black donors fivefold while enhancing the safety of the blood supply.
© 2018 AABB.

Entities:  

Mesh:

Year:  2018        PMID: 30265757     DOI: 10.1111/trf.14959

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  11 in total

1.  Implementation of a script for predonation interviews: impact on human immunodeficiency virus risk in South African blood donors.

Authors:  Josephine Mitchel; Brian Custer; Zhanna Kaidarova; Edward L Murphy; Karin van den Berg
Journal:  Transfusion       Date:  2019-04-04       Impact factor: 3.157

2.  Safe-Testing Algorithm for Individual-Donation Nucleic Acid Testing: 10 Years of Experience in a Low-Prevalence Country.

Authors:  Martin Stolz; Peter Gowland; Caroline Tinguely; Christoph Niederhauser
Journal:  Transfus Med Hemother       Date:  2019-03-12       Impact factor: 3.747

3.  HIV incidence in South African blood donors from 2012 to 2016: a comparison of estimation methods.

Authors:  Marion Vermeulen; Dhuly Chowdhury; Ronel Swanevelder; Eduard Grebe; Donald Brambilla; Ute Jentsch; Michael Busch; Gert Van Zyl; Edward L Murphy
Journal:  Vox Sang       Date:  2020-08-06       Impact factor: 2.144

4.  Undisclosed HIV status and antiretroviral therapy use among South African blood donors.

Authors:  Karin van den Berg; Marion Vermeulen; Vernon J Louw; Edward L Murphy; Gary Maartens
Journal:  Transfusion       Date:  2021-07-05       Impact factor: 3.337

5.  Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) among blood donors: a pilot study, England June 2018 to July 2019.

Authors:  Heli Harvala; Claire Reynolds; Samreen Ijaz; Vicki Maddox; Sujan Dilly Penchala; Alieu Amara; Laura Else; Susan Brailsford; Saye Khoo
Journal:  Sex Transm Infect       Date:  2021-03-29       Impact factor: 3.519

6.  The Impact of Early Antiretroviral Treatment (ART) for HIV on the Sensitivity of the Latest Generation of Blood Screening and Point of Care Assays.

Authors:  Marion Vermeulen; Cari van Schalkwyk; Genevieve Jacobs; Karin van den Berg; Mars Stone; Sonia Bakkour; Brian Custer; Ute Jentsch; Michael P Busch; Edward Murphy; Eduard Grebe
Journal:  Viruses       Date:  2022-06-29       Impact factor: 5.818

7.  10-year analysis of human immunodeficiency virus incidence in first-time and repeat donors in Brazil.

Authors:  Sheila de Oliveira Garcia Mateos; Liliana Preiss; Thelma T Gonçalez; Claudia Di Lorenzo Oliveira; Eduard Grebe; Clara Di Germanio; Mars Stone; Luiz Amorim Filho; Anna Bárbara Carneiro Proietti; Andre Rolim Belisario; Cesar de Almeida-Neto; Alfredo Mendrone-Junior; Paula Loureiro; Michael P Busch; Brian Custer; Ester Cerdeira Sabino
Journal:  Vox Sang       Date:  2020-09-30       Impact factor: 2.144

Review 8.  Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light.

Authors:  Marion C Lanteri; Felicia Santa-Maria; Andrew Laughhunn; Yvette A Girard; Marcus Picard-Maureau; Jean-Marc Payrat; Johannes Irsch; Adonis Stassinopoulos; Peter Bringmann
Journal:  Transfusion       Date:  2020-04-24       Impact factor: 3.157

9.  Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding.

Authors:  Rumbidzai Chitongo; Adetayo Emmanuel Obasa; Sello Given Mikasi; Graeme Brendon Jacobs; Ruben Cloete
Journal:  PLoS One       Date:  2020-05-07       Impact factor: 3.240

10.  An assessment of hepatitis B virus prevalence in South African young blood donors born after the implementation of the infant hepatitis B virus immunization program: Implications for transfusion safety.

Authors:  Marion Vermeulen; Ronel Swanevelder; Gert Van Zyl; Nico Lelie; Edward L Murphy
Journal:  Transfusion       Date:  2021-06-26       Impact factor: 3.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.